Developing new methods for creating pharmaceutical ingredients using hydrogen
Catalytic C-C Coupling via Hydrogen Transfer
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS AT AUSTIN · NIH-10995971
This study is exploring new ways to make important ingredients for medicines more efficiently and cleanly, which could lead to better treatments for patients, including those with cancer or infections.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS AT AUSTIN (nih funded) |
| Locations | 1 site (AUSTIN, UNITED STATES) |
| Trial ID | NIH-10995971 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative catalytic methods for forming carbon-carbon bonds, which are essential in the production of pharmaceutical ingredients. By utilizing hydrogen and other compounds, the team aims to develop cleaner and more efficient processes for synthesizing higher alcohols and amines from lower ones. This work not only enhances the efficiency of chemical reactions but also supports the synthesis of natural products that may have anti-cancer or anti-bacterial properties. Patients may benefit from improved pharmaceutical products resulting from these advanced methods.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals requiring new or improved medications for cancer or bacterial infections.
Not a fit: Patients who are not affected by cancer or bacterial infections may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer pharmaceutical agents for treating various conditions.
How similar studies have performed: Previous research in catalytic methods for pharmaceutical synthesis has shown promising results, indicating that this approach could lead to significant advancements.
Where this research is happening
AUSTIN, UNITED STATES
- UNIVERSITY OF TEXAS AT AUSTIN — AUSTIN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRISCHE, MICHAEL J — UNIVERSITY OF TEXAS AT AUSTIN
- Study coordinator: KRISCHE, MICHAEL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer